Literature DB >> 21565703

Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120.

Brett Spurrier1, Jared M Sampson, Maxim Totrov, Huiguang Li, Timothy O'Neal, Constance Williams, James Robinson, Miroslaw K Gorny, Susan Zolla-Pazner, Xiang-Peng Kong.   

Abstract

The quaternary neutralizing epitope (QNE) of HIV-1 gp120 is preferentially expressed on the trimeric envelope spikes of intact HIV virions, and QNE-specific monoclonal antibodies (mAbs) potently neutralize HIV-1. Here, we present the crystal structures of the Fabs of human mAb 2909 and macaque mAb 2.5B. Both mAbs have long beta hairpin CDR H3 regions >20 Å in length that are each situated at the center of their respective antigen-binding sites. Computational analysis showed that the paratopes include the whole CDR H3, while additional CDR residues form shallow binding pockets. Structural modeling suggests a way to understand the configuration of QNEs and the antigen-antibody interaction for QNE mAbs. Our data will be useful in designing immunogens that may elicit potent neutralizing QNE Abs.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21565703      PMCID: PMC3096878          DOI: 10.1016/j.str.2011.02.012

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  38 in total

1.  Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

Authors:  Marie Pancera; Jason S McLellan; Xueling Wu; Jiang Zhu; Anita Changela; Stephen D Schmidt; Yongping Yang; Tongqing Zhou; Sanjay Phogat; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.

Authors:  Robert Pejchal; Laura M Walker; Robyn L Stanfield; Sanjay K Phogat; Wayne C Koff; Pascal Poignard; Dennis R Burton; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-02       Impact factor: 11.205

3.  Optimal docking area: a new method for predicting protein-protein interaction sites.

Authors:  Juan Fernandez-Recio; Max Totrov; Constantin Skorodumov; Ruben Abagyan
Journal:  Proteins       Date:  2005-01-01

4.  Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.

Authors:  Christian H Bell; Ralph Pantophlet; André Schiefner; Lisa A Cavacini; Robyn L Stanfield; Dennis R Burton; Ian A Wilson
Journal:  J Mol Biol       Date:  2007-11-13       Impact factor: 5.469

5.  Complete nucleotide sequences of functional clones of the AIDS virus.

Authors:  L Ratner; A Fisher; L L Jagodzinski; H Mitsuya; R S Liou; R C Gallo; F Wong-Staal
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

6.  Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.

Authors:  Miroslaw K Gorny; Leonidas Stamatatos; Barbara Volsky; Kathy Revesz; Constance Williams; Xiao-Hong Wang; Sandra Cohen; Robert Staudinger; Susan Zolla-Pazner
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate.

Authors:  M W Cho; M K Lee; C H Chen; T Matthews; M A Martin
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

8.  A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3.

Authors:  Martin Hülsmeyer; Patrick Chames; Roman C Hillig; Robyn L Stanfield; Gerhard Held; Pierre G Coulie; Claudia Alings; Gabriele Wille; Wolfram Saenger; Barbara Uchanska-Ziegler; Hennie R Hoogenboom; Andreas Ziegler
Journal:  J Biol Chem       Date:  2004-11-10       Impact factor: 5.157

9.  Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.

Authors:  W J Honnen; C Krachmarov; S C Kayman; M K Gorny; S Zolla-Pazner; A Pinter
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

10.  Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Authors:  Miroslaw K Gorny; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Kathy Revesz; Bradley Witover; Sherri Burda; Mateusz Urbanski; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner; Arthur Nadas
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

View more
  18 in total

1.  Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.

Authors:  Miroslaw K Gorny; Ruimin Pan; Constance Williams; Xiao-Hong Wang; Barbara Volsky; Timothy O'Neal; Brett Spurrier; Jared M Sampson; Liuzhe Li; Michael S Seaman; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  Virology       Date:  2012-03-07       Impact factor: 3.616

2.  Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV.

Authors:  Brett Spurrier; Jared Sampson; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

3.  SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles.

Authors:  Austin Featherstone; Christopher Aiken
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

4.  Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.

Authors:  Jason S McLellan; Marie Pancera; Chris Carrico; Jason Gorman; Jean-Philippe Julien; Reza Khayat; Robert Louder; Robert Pejchal; Mallika Sastry; Kaifan Dai; Sijy O'Dell; Nikita Patel; Syed Shahzad-ul-Hussan; Yongping Yang; Baoshan Zhang; Tongqing Zhou; Jiang Zhu; Jeffrey C Boyington; Gwo-Yu Chuang; Devan Diwanji; Ivelin Georgiev; Young Do Kwon; Doyung Lee; Mark K Louder; Stephanie Moquin; Stephen D Schmidt; Zhi-Yong Yang; Mattia Bonsignori; John A Crump; Saidi H Kapiga; Noel E Sam; Barton F Haynes; Dennis R Burton; Wayne C Koff; Laura M Walker; Sanjay Phogat; Richard Wyatt; Jared Orwenyo; Lai-Xi Wang; James Arthos; Carole A Bewley; John R Mascola; Gary J Nabel; William R Schief; Andrew B Ward; Ian A Wilson; Peter D Kwong
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

5.  Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.

Authors:  Xunqing Jiang; Max Totrov; Wei Li; Jared M Sampson; Constance Williams; Hong Lu; Xueling Wu; Shan Lu; Shixia Wang; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

6.  Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses.

Authors:  Ann J Hessell; Rebecca Powell; Xunqing Jiang; Christina Luo; Svenja Weiss; Vincent Dussupt; Vincenza Itri; Alisa Fox; Mariya B Shapiro; Shilpi Pandey; Tracy Cheever; Deborah H Fuller; Byung Park; Shelly J Krebs; Maxim Totrov; Nancy L Haigwood; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  Cell Rep       Date:  2019-07-23       Impact factor: 9.423

7.  The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Authors:  Nicos Karasavvas; Erik Billings; Mangala Rao; Constance Williams; Susan Zolla-Pazner; Robert T Bailer; Richard A Koup; Sirinan Madnote; Duangnapa Arworn; Xiaoying Shen; Georgia D Tomaras; Jeffrey R Currier; Mike Jiang; Craig Magaret; Charla Andrews; Raphael Gottardo; Peter Gilbert; Timothy J Cardozo; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Robert Paris; Kelli Greene; Hongmei Gao; Sanjay Gurunathan; Jim Tartaglia; Faruk Sinangil; Bette T Korber; David C Montefiori; John R Mascola; Merlin L Robb; Barton F Haynes; Viseth Ngauy; Nelson L Michael; Jerome H Kim; Mark S de Souza
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

8.  Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages.

Authors:  Ruijun Zhang; Laurent Verkoczy; Kevin Wiehe; S Munir Alam; Nathan I Nicely; Sampa Santra; Todd Bradley; Charles W Pemble; Jinsong Zhang; Feng Gao; David C Montefiori; Hilary Bouton-Verville; Garnett Kelsoe; Kevin Larimore; Phillip D Greenberg; Robert Parks; Andrew Foulger; Jessica N Peel; Kan Luo; Xiaozhi Lu; Ashley M Trama; Nathan Vandergrift; Georgia D Tomaras; Thomas B Kepler; M Anthony Moody; Hua-Xin Liao; Barton F Haynes
Journal:  Sci Transl Med       Date:  2016-04-27       Impact factor: 17.956

9.  Rabbit anti-HIV-1 monoclonal antibodies raised by immunization can mimic the antigen-binding modes of antibodies derived from HIV-1-infected humans.

Authors:  Ruimin Pan; Jared M Sampson; Yuxin Chen; Michael Vaine; Shixia Wang; Shan Lu; Xiang-Peng Kong
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

10.  Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1.

Authors:  Hua-Xin Liao; Chun-Yen Tsao; S Munir Alam; Mark Muldoon; Nathan Vandergrift; Ben-Jiang Ma; Xiaozhi Lu; Laura L Sutherland; Richard M Scearce; Cindy Bowman; Robert Parks; Haiyan Chen; Julie H Blinn; Alan Lapedes; Sydeaka Watson; Shi-Mao Xia; Andrew Foulger; Beatrice H Hahn; George M Shaw; Ron Swanstrom; David C Montefiori; Feng Gao; Barton F Haynes; Bette Korber
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.